Article Text

Download PDFPDF
Non-steroidal anti-inflammatory treatment during covid-19: friend or foe? Response to: ‘Coronavirus disease 19 (Covid-19) and non-steroidal anti-inflammatory drugs (NSAID)’ by Giollo et al
  1. Sara Monti,
  2. Carlomaurizio Montecucco
  1. Rheumatology, Fondazione IRCCS Policlinico San Matteo, Pavia, Lombardia, Italy
  1. Correspondence to Dr Sara Monti, Rheumatology, Fondazione IRCCS Policlinico San Matteo, Pavia 27100, Italy; sara.saramonti{at}gmail.com

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We thank Dr Giollo et al 1 for their interest and comment on our published paper on the outcome of covid-19 in patients with rheumatic diseases.2 The authors highlighted the importance of reporting on the use of non-steroidal anti-inflammatory drugs (NSAIDS) commonly prescribed to patients with chronic arthritis. The effect of NSAIDS on the course of covid-19 is still unknown. It can be speculated that NSAIDs might have a beneficial role in the …

View Full Text

Footnotes

  • Handling editor Josef S Smolen

  • Contributors SM and CM contributed equally to the article.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Patient consent for publication Not required.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles